SML2840
AZD2066
≥98% (HPLC)
别名:
4-[5-[(1R)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine, AZD 2066
产品名称
AZD2066, ≥98% (HPLC)
SMILES string
Clc1cc(ccc1)c2[o]nc(c2)[C@H](Oc3[n](c(nn3)c4ccncc4)C)C
InChI
1S/C19H16ClN5O2/c1-12(16-11-17(27-24-16)14-4-3-5-15(20)10-14)26-19-23-22-18(25(19)2)13-6-8-21-9-7-13/h3-12H,1-2H3/t12-/m1/s1
InChI key
SXWHYTICXCLKDG-GFCCVEGCSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
AZD2066 is an orally bioavailable, brain penetrant, selective and potent negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGlu5). AZD2066 exhibited satisfactory efficacy in patients suffering from neuropathic pain with mechanical hypersensitivity.
orally bioavailable, brain penetrant, selective and potent negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGlu5)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Brittany A Jaso et al.
Current neuropharmacology, 15(1), 57-70 (2016-03-22)
Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset that can prolong distress and impairment for patients, and realworld effectiveness trials further suggest that antidepressant efficacy is limited in many patients. All currently approved antidepressant medications
Matts Kågedal et al.
NeuroImage, 82, 160-169 (2013-05-15)
AZD2066 is a new chemical entity pharmacologically characterized as a selective, negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5). Antagonism of mGluR5 has been implicated in relation to various diseases such as anxiety, depression, and pain disorders.
Michael D B Swedberg et al.
The Journal of pharmacology and experimental therapeutics, 350(2), 212-222 (2014-05-31)
The metabotropic glutamate receptor 5 (mGluR5) antagonists fenobam, MPEP (2-methyl-6-(phenylethynyl)pyridine), and MTEP (3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine) were previously shown to not cause N-methyl-D-aspartate antagonist-like psychoactive effects in phencyclidine (PCP) drug discrimination studies, but to cause MTEP-like discrimination in rats, suggesting that the psychoactive
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持